- Mid-January 2024: Supply disruptions of Levemir® FlexPen®
- April 1, 2024: Discontinuation of Levemir® FlexPen®
- December 31, 2024: Full brand discontinuation, including Levemir® vial
Discontinuation Notice: Levemir Products to be Discontinued from January 2024
November 8, 2024 -- Due to global manufacturing constraints, formulary losses impacting patient access, and the availability of alternative options, Novo Nordisk will be discontinuing Levemir® in the U.S.
The company will continue to provide Levemir® FlexPen® and Levemir® vials to wholesalers while supplies last, up to the discontinuation dates, but supply disruptions should be expected.
Novo Nordisk's top priority is always the health and safety of the patients that use our products. The company made this decision after careful consideration, and is confident that patients will be able to access alternative treatments in the U.S.
The company recommends that healthcare providers talk to their patients about alternative treatment options in advance of this supply disruption and discontinuation to ensure continuity of care.
Source: Novo Nordisk
Reference: Levemir Product Information
Posted November 2023
Read this next
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
Men Face More Diabetes Complications Than Women
FRIDAY, May 17, 2024 -- Men with diabetes have a greater risk for complications than women, irrespective of diabetes duration, according to a study published online May 16 in...
AI-Informed Health App Aids Diabetes Outcomes
WEDNSDAY, May 15, 2024 -- Use of an artificial intelligence (AI)-informed health app aids diabetes outcomes and cuts atherosclerotic cardiovascular disease (ASCVD) risk, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.